Ionis Pharma: Clinical Study of Vupanorsen Meets Primary Endpoint

By Robb M. Stewart

Ionis Pharmaceuticals Inc. said a clinical study of vupanorsen, an investigational antisense therapy being developed for indications in cardiovascular risk reduction and severe hypertriglyceridemia that it licensed from Pfizer Inc., met its main targets.

Pfizer reported topline results from a Phase 2b study which found vupanorsen met its primary endpoint, achieving statistically significant reduction in non-high density lipoprotein cholesterol compared with a placebo at all doses tested, Ionis said Wednesday.

The study's key secondary endpoints were met, including statistically significant reductions in triglycerides and angiopoietin-like-3 at all doses tested, Ionis said.

The company said Pfizer is continuing to review the findings to determine the next steps for future development.

Vupanorsen was discovered by Ionis and is being developed by Pfizer, which licensed it from Ionis in November 2019 in a worldwide exclusive agreement.

In premarket trading, Ionis's shares were 1.2% higher after ending the previous session at $30.33, down 46% since the end of last year.

Write to Robb M. Stewart at [e-mail]

(END) Dow Jones Newswires

November 24, 2021 07:14 ET (12:14 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.